# To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

> **NCT05852431** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **89bio, Inc.** · enrollment: 360 (estimated)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Pegozafermin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05852431
- **Lead sponsor:** 89bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-15
- **Primary completion:** 2025-07-07
- **Final completion:** 2026-04
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05852431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05852431, "To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05852431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*